Analysis of Treatment Pattern of Antiplatelet in First-Ever Ischemic Stroke Without Previous Antiplatelet Use: A Real-World Distributed Network Analysis of 11 Observational Korean Databases Using a Common Data Model Authors: Soo-Hyun Park, Kyung Joo Lee, Jinseob Kim, Seung In Seo, Dong Yun Lee, Rae Woong Park, Sang Youl Rhee, Jae Myung Cha, Hyeon-Jong Yang, Jae-Won Jang, Seunguk Jung, Jeeun Lee, Minwoo Lee, Sang-Hwa Lee, Chulho Kim, Jong Seok Bae, Yeo Jin Kim, Ju-Hun Lee, Yerim Kim Published: 2025 ABSTRACT AbstractBackgroundAntiplatelet agents are widely prescribed to prevent cardiovascular events, with cardiovascular disease being the leading global cause of death and the second most common in Korea. As the demand for antiplatelets increases, understanding real-world prescribing patterns is essential.MethodsThis study analyzed antiplatelet prescription trends for patients with first-ever ischemic stroke (IS) using 11 Korean observational databases transformed to a Common Data Model, spanning 1995–2023. Prescription shifts were assessed in relation to the 2013 CHANCE trial.ResultsThe analysis included 162,361 patients with first-ever IS who had no prior antiplatelet therapy. Aspirin was the most commonly prescribed initial medication (39.4%), followed by aspirin-clopidogrel combination (28.2%), clopidogrel alone (13.7%), and cilostazol (5.0%). Initial medication were typically maintained: however, some patients initially on aspirin or clopidogrel switched to dual antiplatelet therapy (DAPT; aspirin and clopidogrel), while those on initial DAPT primarily transitioned to clopidogrel, then to aspirin. Following the CHANCE trial, a marked shift in prescription patterns was observed. Before CHANCE, aspirin was predominant (45.7%), followed by aspirin-clopidogrel (19.2%), and clopidogrel (15.5%). Post-CHANCE, aspirin-clopidogrel became the leading therapy (40.6%), with aspirin (30.3%) and clopidogrel (11.3%) monotherapy.ConclusionWhile aspirin remains the mainstay for secondary prevention of IS, the CHANCE trial significantly influenced increased use of DAPT. As evidence continues to grow for P2Y12 inhibitors in the IS context, analyzing antiplatelet prescription patterns is vital for evaluating the implementation of guidelines in clinical practice.Keywords: Aspirin, Cerebral Infarction, Clopidogrel, Ischemic Stroke, Stroke, Standard of Care INTRODUCTION Cardiovascular diseases constitute a significant global health challenge and are particularly impactful in Korea, where they are the second leading cause of death.1 Antiplatelet agents play a crucial role in the secondary prevention of these conditions, and their use is expected to increase. The field of antiplatelet therapy is characterized by rapid advancements in medication options and updates to clinical guidelines. A comprehensive analysis of prescription patterns is essential to understand how healthcare providers are responding to these changes and implementing new evidence into practice. Despite the longstanding use of aspirin as an antiplatelet agent, recent guidelines advise against its use for primary prevention.2 Previous studies have shown that combining clopidogrel and aspirin does not decrease the risk of recurrent ischemic stroke (IS) but does increase the risk of major bleeding events.3,4 Conversely, recent findings support the superiority of dual antiplatelet therapy (DAPT)—specifically, the combination of aspirin and clopidogrel—over aspirin alone in the secondary prevention of IS.5,6 This shift highlights the evolving patterns of antiplatelet treatment in secondary prevention. The emergence of new P2Y12 inhibitors in the treatment of IS further underscores the importance of analyzing prescription trends to ensure alignment with the latest clinical guidelines using real-world data. The aim of this study is to evaluate the prescription patterns of antiplatelets in patients experiencing their first IS without prior antiplatelet treatment. We also explore changes in these patterns following a pivotal trial, providing insights into the adaptation of clinical practice considering new evidence. METHODS Data sources This study explored the prescription patterns in patients experiencing their first IS by utilizing a real-world distributed network analysis across 11 observational Korean databases converted into a Common Data Model (CDM) from 1995 to 2023. This research encompassed roughly 13 million patient-based retrospective cohort records from 11 hospitals (Ajou University Medical Center [AUMC], Gyeongsang National University Changwon Hospital [GNUCH], Kangdong Sacred Heart Hospital [KDH], Kyung Hee University Medical Center [KHMC], Kyung Hee University Hospital at Gangdong [KHNMC], Kangwon Medical Center [KWMC], Myongji Hospital [MJH], Soonchunhyang University Bucheon Hospital [SCHBC], Soonchunhyang University Gumi Hospital [SCHGM], Soonchunhyang University Cheonan Hospital [SCHCA], Soonchunhyang University Seoul Hospital [SCHSU]), which were integrated into the Observational Medical Outcomes Partnership (OMOP) CDM. The Observational Health Data Sciences and Informatics (OHDSI) initiative, a global collaborative group, aims to facilitate robust evidence generation using open-source data analysis tools across a broad network of healthcare databases worldwide. This group also provides continual support and updates to the OMOP CDM database.7 Since 2016, in association with the nationwide cohort database in Korea, Ajou University has successfully implemented the OMOP CDM model and verify its accuracy.8 This study incorporated patient-based retrospective cohort data from five medical centers including Ajou University Medical Center (n = 2,959,803), Kangdong Sacred Heart Hospital, Hallym University College of Medicine (n = 1,209,068), Kyung Hee University Medical Center (n = 1,222,935), Gangdong Kyung Hee University Hospital (n = 880,275), Kangwon National University Hospital (n = 569,218), Gyeongsang National University Changwon Hospital (n = 333,345), Myongji Hospital (n = 1,039,519), Soonchunhyang University Bucheon Hospital (n = 1,301,117), Soonchunhyang University Gumi Hospital (n = 632,252), Soonchunhyang University Cheonan Hospital (n = 987,701), and Soonchunhyang University Seoul Hospital (n = 1,098,041), all converted to OMOP CDM. The baseline characteristics of the eleven databases are summarized in Table 1. Table 1Baseline characteristics of the included eleven hospital databasesVariablesTotalAUMCGNUCHKDHKHMCKHNMCKWMCMJHSCHBCSCHGMSCHCASCHSUTotal162,36121,4553,34312,22442,25216,9829,0909,69316,44410,88910,6729,317Male83,172 (51.2)12,443 (58.0)1,363 (40.8)6,642 (54.3)20,946 (49.6)8,090 (47.6)4,974 (54.7)4,918 (50.7)8,079 (49.1)6,131 (56.3)5,116 (47.9)4,470 (48.0)Age group, yr15–191717 (0.1)25–296060 (0.4)30–34716282 (1.3)101 (1.0)178 (1.1)57 (1.1)98 (1.1)35–392,496505 (2.3)47 (1.4)150 (1.2)522 (1.2)206 (1.2)102 (1.1)213 (2.2)337 (2.1)94 (1.8)152 (1.4)168 (1.8)40–444,506837 (3.9)82 (2.5)322 (2.6)975 (2.3)408 (2.4)174 (1.9)353 (3.6)650 (4 0)167 (3.1)292 (2.7)246 (2.6)45–498,1181,271 (5.9)162 (4.9)639 (5.2)1,984 (4.7)813 (4.8)302 (3.3)541 (5.6)1,099 (6.7)316 (5.9)534 (4.9)457 (4.9)50–5412,8821,860 (8.7)234 (7.0)992 (8.1)3,558 (8.4)1,451 (8.5)511 (5.6)717 (7.4)1,533 (9.3)450 (8.4)812 (7.5)764 (8.2)55–5916,9522,471 (11.5)300 (9.0)1,399 (11.4)4,863 (11.5)1,897 (11.2)771 (8.5)866 (8.9)1,751 (10.7)541 (10.1)1,080 (9.9)1,013 (10.9)60–6420,4022,928 (13.7)405 (12.1)1,636 (13.4)5,869 (13.9)2,176 (12.8)1,059 (11.7)1,089 (11.2)2,178 (13.2)617 (11.6)1,179 (10.8)1,266 (13.6)65–6923,0163,029 (14.1)432 (12.9)1,644 (13.5)7,046 (16.0)2,478 (14.6)1,206 (13.3)1,280 (13.2)2,370 (14.4)727 (13.6)1,468 (13.5)1,336 (14.3)70–7423,7723,005 (14.0)438 (13.1)1,684 (13.8)7,053 (16.7)2,503 (14.7)1,399 (15.4)1,465 (15.1)2,335 (14.2)762 (14.3)1,790 (16.4)1,338 (14.4)75–7920,5672,425 (11.3)500 (15.0)1,558 (12.8)5,570 (13.2)2,295 (13.5)1,488 (16.4)1,277 (13.2)1,888 (11.5)734 (13.8)1,691 (15.5)1,141 (12.3)80–8413,1501,529 (7.1)424 (12.7)1,130 (9.2)2,916 (6.9)1,548 (9.1)1,116 (12.3)931 (9.6)1,224 (7.4)490 (9.2)1,023 (9.4)819 (8.8)85–895,880664 (3.1)234 (7.0)581 (4.8)1,028 (2.4)710 (4.2)575 (6.3)496 (5.1)495 (3.0)253 (4.7)445 (4.1)399 (4.3)90–941,277181 (0.8)42 (1.3)210 (1.7)203 (1.2)182 (2.0)145 (1.5)57 (1.1)126 (1.2)131 (1.4)Risk factorsHypertension55,876 (34.4)7,723 (36.0)372 (11.1)1,674 (137.0)16,083 (38.1)4,669 (27.5)1,442 (15.9)3,947 (40.7)7,711 (46.9)5,048 (46.4)3,058 (28.7)4,149 (44.5)Diabetes26,925 (16.6)3,863 (18.0)293 (8.8)967 (7.9)6,904 (16.3)2,419 (14.2)925 (10.2)1,690 (17.4)3,436 (20.9)2,536 (23.3)1,612 (15.1)2,280 (24.5)Dyslipidemia21,542(13.3)649 (3.0)28 (0.8)297 (2.4)8,117 (19.2)2,025 (11.9)636 (7.0)2,711 (28.0)2,390 (14.5)1,114 (10.2)1,690 (15.8)1,885 (20.2)Atrial fibrillation3,890 (2.4)467 (2.2)44 (1.3)132 (1.1)704 (1.7)342 (2.0)357 (3.9)370 (3.8)316 (1.9)545 (5.0)254 (2.4)359 (3.9)Smoking3,602 (2.2)0 (0)69 (2.1)72 (0.6)1,144 (2.7)0 (0)0 (0)16 (0.2)646 (3.9)628 (5.8)518 (4.9)509 (5.5)Values are presented as number (%).AUMC = Ajou University Medical Center, GNUCH = Gyeongsang National University Changwon Hospital, KDH = Kangdong Sacred Heart Hospital, KHMC = Kyung Hee University Mmedical Center, KHNMC = Kyung Hee University Hospital at Gangdong, KWMC = Kangwon Medical Center, MJH = Myongji Hospital, SCHBC = Soonchunhyang University Buchoen Hospital, SCHGM = Soonchunhyang University Gumi Hospital, SCHCA = Soonchunhyang University Cheonan Hospital, SCHSU = Soonchunhyang University Seoul Hospital. Baseline characteristics of the included eleven hospital databases Values are presented as number (%). AUMC = Ajou University Medical Center, GNUCH = Gyeongsang National University Changwon Hospital, KDH = Kangdong Sacred Heart Hospital, KHMC = Kyung Hee University Mmedical Center, KHNMC = Kyung Hee University Hospital at Gangdong, KWMC = Kangwon Medical Center, MJH = Myongji Hospital, SCHBC = Soonchunhyang University Buchoen Hospital, SCHGM = Soonchunhyang University Gumi Hospital, SCHCA = Soonchunhyang University Cheonan Hospital, SCHSU = Soonchunhyang University Seoul Hospital. Study design and cohort definition We conducted a retrospective, observational cohort study including all patients experiencing their first-ever IS who had not previously used antiplatelet medications. This analysis encompassed 162,361 patients from 11 datasets, all of whom had their first-ever IS and no prior antiplatelet usage. The antiplatelet medications considered were aspirin, clopidogrel, cilostazol, triflusal, and ticagrelor. We excluded sarpogrelate and prasugrel, as current guidelines do not recommend them for secondary stroke prevention. Similarly, ticlopidine was excluded due to its classification within the same thienopyridine group as clopidogrel and ticagrelor, and its significant decline in use following reports of severe side effects including fatal blood dyscrasias. We further analyzed prescription patterns changes surrounding the landmark CHANCE trial, which was published on July 4, 2013. Analyses were conducted separately for periods before and after this date.5 Additional studies were performed to assess the treatment patterns of antiplatelets among patients with first-ever IS with concurrent coronary artery disease or carotid stenosis. Statistical analysis and treatment pathway We utilized OHDSI analysis tools integrated into the ATLAS platform and the OHDSI Methods Library R packages, available at https://github.com/OHDSI/. The analyses were performed using ATLAS version 2.7.3, with data processed through the FEEDER-NET platform, a large-scale health data platform that operates on the OMOP CDM framework and is supported by a Korean national project. To visualize medication sequences, we generated sunburst plots using software coded in HTML5 and JavaScript, employing Data-Driven Documents. These tools and resources are accessible via OHDSI.org. Ethics statement This study received approval from the Institutional Review Board (IRB) of the Kangdong Sacred Heart Hospital (IRB No. 2023-04-014) and adhered to the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients or their representatives. RESULTS From the databases of eleven hospitals, 162,361 subjects diagnosed with their first-ever IS were included in this study. Detailed characteristics of the cohorts are provided in Table 1. Because thousands of diseases and medications are included, we cannot show all factors in the table. Males accounted for 51.2% of the subjects and the age range of the participants was 15–94 years. Of these patients, 43,097 (39.4%) were treated with aspirin, 30,778 (28.2%) with both aspirin and clopidogrel, 14,984 (13.7%) with clopidogrel alone, 5,479 (5.0%) with cilostazol, and 4,802 (4.4%) with both aspirin and cilostazol (Table 2 and Fig. 1). The treatment pathways for these antiplatelet therapies are depicted as sunburst plots in Fig. 2 and detailed in Table 3. For the primary treatment pathway, the initial medication was continued in all cases (aspirin group: 57.2%, clopidogrel group: 66.4%, aspirin and clopidogrel group: 36.2%, and cilostazol group: 66.3%). As a secondary pathway, except in cases where the initial medication was continued, in the aspirin group (Fig. 2A) and clopidogrel group (Fig. 2B), the initial medication was switched to DAPT (aspirin plus clopidogrel) (16.3% and 14.9%), whereas in the initial DAPT group, DAPT was switched to clopidogrel (32.5%), followed by aspirin (17.9%) (Fig. 2C). Table 2Initial treatment option of antiplatelet pathway in first-ever ischemic stroke without previous any platelet useInitial treatment antiplateletNo. (%)Aspirin43,097 (39.4)Aspirin + clopidogrel30,778 (28.2)Aspirin + cilostazol4,802 (4.4)Aspirin + clopidogrel + cilostazol2,154 (1.8)Aspirin + clopidogrel + cilostazol + ticagrelor2 (< 0.1)Aspirin + clopidogrel + cilostazol + triflusal87 (< 0.1)Aspirin + cilostazol + ticagrelor4 (< 0.1)Aspirin + cilostazol + triflusal77 (< 0.1)Aspirin + clopidogrel + ticagrelor75 (< 0.1)Aspirin + clopidogrel + ticagrelor + triflusal2 (< 0.1)Aspirin + clopidogrel + triflusal483 (0.4)Aspirin + ticagrelor148 (0.1)Aspirin + triflusal1,451 (1.3)Clopidogrel14,984 (13.7)Clopidogrel + cilostazol861 (0.8)Clopidogrel + cilostazol + triflusal27 (< 0.1)Clopidogrel + triflusal319 (0.3)Cilostazol5,479 (5.0)Cilostazol + triflusal235 (0.2)Ticagrelor3 (< 0.1)Triflusal4,258 (3.9)Total109,326 Initial treatment option of antiplatelet pathway in first-ever ischemic stroke without previous any platelet use Initial treatment option of the antiplatelet pathway in first-ever ischemic stroke without previous platelet use. The treatment pathways for the selected antiplatelets are illustrated as sunburst plots. (A) Aspirin group using aspirin as first choice, (B) clopidogrel group using clopidogrel as first choice, (C) aspirin plus clopidogrel group using aspirin plus clopidogrel as first choice, (D) cilostazol group using cilostazol as first choice. Table 3Antiplatelet pathway in first-ever ischemic stroke without previous any platelet uses according to the first taken antiplateletPrimary treatmentSecondary treatmentNo. (%)Aspirin43,097AspirinMaintain aspirin24,659 (57.2)AspirinAspirin + cilostazol2,931 (6.8)AspirinAspirin + clopidogrel7,012 (16.3)AspirinAspirin + clopidogrel + cilostazol291 (0.7)AspirinAspirin + clopidogrel + ticagrelor25 (0.1)AspirinAspirin + cilostazol + triflusal6 (0.0)AspirinAspirin + clopidogrel + triflusal28 (0.1)AspirinAspirin + clopidogrel + cilostazol + triflusal3 (0.0)AspirinAspirin + ticagrelor59 (0.1)AspirinAspirin + triflusal456 (1.1)AspirinCilostazol1,723 (4.0)AspirinCilostazol + triflusal27 (0.1)AspirinClopidogrel4,478 (10.4)AspirinClopidogrel + cilostazol109 (0.3)AspirinClopidogrel + cilostazol + triflusal1 (0.0)AspirinClopidogrel + triflusal56 (0.1)AspirinTicagrelor1 (0.0)AspirinTriflusal1,232 (2.9)Clopidogrel14,984ClopidogrelMaintain clopidogrel9,949 (66.4)ClopidogrelAspirin1,024 (6.8)ClopidogrelAspirin + cilostazol130 (0.9)ClopidogrelAspirin + clopidogrel + cilostazol133 (0.9)ClopidogrelAspirin + cilostazol + ticagrelor1 (0.0)ClopidogrelAspirin + cilostazol + triflusal1 (0.0)ClopidogrelAspirin + clopidogrel2,229 (14.9)ClopidogrelAspirin + clopidogrel + ticagrelor10 (0.1)ClopidogrelAspirin + clopidogrel + triflusal29 (0.2)ClopidogrelAspirin + ticagrelor5 (0.0)ClopidogrelAspirin + triflusal7 (0.0)ClopidogrelCilostazol525 (3.5)ClopidogrelClopidogrel + cilostazol513 (3.4)ClopidogrelClopidogrel + cilostazol + triflusal7 (0.0)ClopidogrelCilostazol + triflusal10 (0.1)ClopidogrelClopidogrel + triflusal147 (1.0)ClopidogrelTriflusal264 (1.8)Cilostazol5,479CilostazolMaintain cilostazol3,634 (66.3)CilostazolAspirin315 (5.7)CilostazolAspirin + cilostazol409 (7.5)CilostazolAspirin + clopidogrel + cilostazol153 (2.8)CilostazolAspirin + clopidogrel + cilostazol + ticagrelor2 (0.0)CilostazolAspirin + cilostazol + ticagrelor1 (0.0)CilostazolAspirin + cilostazol + triflusal3 (0.1)CilostazolAspirin + clopidogrel155 (2.8)CilostazolAspirin + clopidogrel + ticagrelor2 (0.0)CilostazolAspirin + clopidogrel + triflusal4 (0.1)CilostazolAspirin + ticagrelor3 (0.1)CilostazolAspirin + triflusal2 (0.0)CilostazolClopidogrel + cilostazol222 (4.1)CilostazolClopidogrel + cilostazol + triflusal5 (0.1)CilostazolCilostazol + triflusal77 (1.4)CilostazolClopidogrel343 (6.3)CilostazolClopidogrel + triflusal10 (0.2)CilostazolTriflusal139 (2.5)Aspirin + clopidogrel30,778Aspirin + clopidogrelMaintain aspirin + clopidogrel11,146 (36.2)Aspirin + clopidogrelAspirin5,502 (17.9)Aspirin + clopidogrelAspirin + cilostazol1,009 (3.3)Aspirin + clopidogrelAspirin + clopidogrel + cilostazol1,432 (4.7)Aspirin + clopidogrelAspirin + clopidogrel + cilostazol + triflusal3 (0.0)Aspirin + clopidogrelAspirin + cilostazol + ticagrelor2 (0.0)Aspirin + clopidogrelAspirin + cilostazol + triflusal2 (0.0)Aspirin + clopidogrelAspirin + clopidogrel + ticagrelor22 (0.1)Aspirin + clopidogrelAspirin + clopidogrel + triflusal146 (0.5)Aspirin + clopidogrelAspirin + ticagrelor29 (0.1)Aspirin + clopidogrelAspirin + triflusal36 (0.1)Aspirin + clopidogrelCilostazol439 (1.4)Aspirin + clopidogrelClopidogrel + cilostazol288 (0.9)Aspirin + clopidogrelClopidogrel + cilostazol + triflusal17 (0.1)Aspirin + clopidogrelCilostazol + triflusal38 (0.1)Aspirin + clopidogrelClopidogrel9,991 (32.5)Aspirin + clopidogrelClopidogrel + triflusal422 (1.4)Aspirin + clopidogrelTriflusal254 (0.8) Antiplatelet pathway in first-ever ischemic stroke without previous any platelet uses according to the first taken antiplatelet Following the landmark CHANCE trial, there was a significant shift in the prescription patterns of antiplatelet drugs. Prior to the trial’s publication, aspirin was the most commonly prescribed therapy (45.7%), followed by combined aspirin and clopidogrel (19.2%), and clopidogrel alone (15.5%). Post-trial, the use of combined aspirin and clopidogrel rose to become the predominant treatment (40.6%), with aspirin (30.3%) and clopidogrel (11.3%) following (Table 4 and Fig. 3). Table 4Initial treatment option of antiplatelet pathway in first-ever ischemic stroke without previous any platelet uses before and after pivotal CHANCE trail (4 July 2013)AntiplateletBeforeAfterAspirin28,920 (45.7)13,937 (30.3)Aspirin + clopidogrel12,177 (19.2)18,675 (40.6)Aspirin + cilostazol2,680 (4.2)2,129 (4.6)Aspirin + clopidogrel + cilostazol777 (1.2)1,382 (3.0)Aspirin + clopidogrel + cilostazol + triflusal49 (0.1)38 (0.1)Aspirin + clopidogrel + cilostazol + ticagrelorNA2 (0.0)Aspirin + cilostazol + triflusal63 (0.1)14 (0.0)Aspirin + cilostazol + ticagrelorNA4 (0.0)Aspirin + clopidogrel + ticagrelor10 (0.0)65 (0.1)Aspirin + clopidogrel + triflusal214 (0.3)265 (0.6)Aspirin + clopidogrel+ ticagrelor + triflusalNA2 (0.0)Aspirin + ticagrelor36 (0.1)118 (0.3)Aspirin + triflusal1,368 (2.2)80 (0.2)Clopidogrel9,813 (15.5)5,219 (11.3)Clopidogrel + cilostazol519 (0.8)342 (0.7)Clopidogrel + cilostazol + triflusal18 (0.0)9 (0.0)Clopidogrel + triflusal219 (0.3)100 (0.2)Cilostazol2,507 (4.0)3,065 (6.7)Cilostazol + triflusal213 (0.3)22 (0.0)TicagrelorNA3 (0.0)Triflusal3,712 (5.9)583 (1.3)Total63,29546,054Values are presented as number (%).NA = not applicable. Initial treatment option of antiplatelet pathway in first-ever ischemic stroke without previous any platelet uses before and after pivotal CHANCE trail (4 July 2013) Values are presented as number (%). NA = not applicable. Initial treatment option of the antiplatelet pathway in first-ever ischemic stroke without previous antiplatelet uses before and after pivotal CHANCE trial (4 July 2013). (A) Before the pivotal trial, (B) after the pivotal trial, (C) changes in antiplatelet prescription proportions before and after the CHANCE trial. Among 2,140 first-ever IS patients with newly diagnosed carotid stenosis and 4,896 with newly diagnosed coronary artery disease, DAPT (aspirin and clopidogrel) was the most common initial antiplatelet choice (41.9% and 44.3%, respectively), followed by aspirin (23.7% and 29.7%) (Fig. 4). Initial treatment option of the antiplatelet pathway in first-ever ischemic stroke without previous antiplatelet uses with (A) newly diagnosed carotid stenosis and (B) with newly diagnosed coronary artery disease. DISCUSSION In this study, we investigated the trends in antiplatelet treatment using data from 11 hospitals converted to the OMOP CDM. Our primary finding reveals that aspirin, traditionally favored for secondary prevention of initial IS, remains the most common choice. However, following the pivotal 2013 CHANCE study, there has been a marked shift toward DAPT, which involves the combination of aspirin and clopidogrel. This approach has become more prevalent than the use of aspirin alone. To our knowledge, this study is the first to explore how landmark trials impact changes in medication prescribing patterns in IS patients in actual clinical practice, using the OMOP CDM framework. This study utilized data converted to CDM format according to the data collection protocol of each participating hospital. In particular, records from Kangdong Sacred Heart Hospital and Ajou University Hospital, which had the most extensive historical data of approximately 20 years, were included, indicating that the use of aspirin, a traditional antiplatelet agent, was high. Recent literature increasingly supports clopidogrel’s superiority over aspirin,9,10 suggesting a potential decline in aspirin’s utilization if analyses were confined to more contemporary data. The publication of the CHANCE study has prompted significant reconsideration of antiplatelet strategies in patients with IS.5 Earlier trials, such as MATCH,3 which compared the combination of aspirin and clopidogrel with clopidogrel alone, and CHARISMA,4 which compared it with aspirin alone, did not demonstrate a significant benefit in vascular outcomes from combination therapy over monotherapy. However, these earlier studies also associated combination therapy with a higher risk of major hemorrhages. Consequently, guidelines have been recommended against the prolonged use of DAPT.11 In contrast, the CHANCE trial demonstrated that, among patients with transient ischemic attack (TIA) or minor stroke, the combination of clopidogrel and aspirin was superior to aspirin alone in reducing the risk of subsequent stroke within the first 21 days, without increasing hemorrhage risks.5 Conducted solely in China, the CHANCE study faced criticisms for its potential lack of generalizability due to the high stroke incidence and low rates of vascular risk management in the study population.12,13 Nonetheless, it marked the first large-scale clinical trial to demonstrate the effectiveness of short-duration combination therapy, specifically during the acute stage of the condition. Subsequently, the POINT trial, which included an international cohort, also showed a reduced risk of major ischemic events at 90 days with combination therapy compared to aspirin alone,6 thereby reinforcing the option of using DAPT as an initial antiplatelet strategy in patients with minor stroke or TIA. The updated 2014 stroke prevention guidelines consequently included a new recommendation to consider this combination for the first 21 days following a minor IS or TIA.14 Despite these developments, it remains unclear how these recommendations have influenced actual antiplatelet prescription practices. To the best of our knowledge, this study is the first to use a real-world data network analysis to explore changes in antiplatelet prescription patterns in patients with first-ever IS following the CHANCE trial. Interestingly, unlike the groups receiving aspirin or clopidogrel, the cilostazol group was more likely to add aspirin rather than combine aspirin with clopidogrel in the step 2 pathway. This preference may reflect the physician’s intention to continue using cilostazol because patients on this medication typically exhibit a significant burden of small vessel disease or a high risk of hemorrhage, as indicated by prior research.15,16 Another notable observation from our study is that the use of ticagrelor, either alone or in combination with another antiplatelet agent, was exceedingly rare, accounting for less than 1% of cases. In comparison, among patients experiencing their first IS with coronary artery disease, 1.7% were treated with both aspirin and ticagrelor. This choice is supported by the superior efficacy of ticagrelor over clopidogrel in patients harboring two CYP2C19 loss-of-function alleles, as the PLATO trial suggests.17 However, the efficacy of ticagrelor in preventing strokes remains a subject of debate. The recent Acute Stroke or Transient Ischaemic Attack Treated with THALES trial showed that DAPT with ticagrelor and aspirin could benefit patients with moderate IS.18 Moreover, a recent network meta-analysis involving 26 randomized clinical trials with 124,495 participants found that adding ticagrelor to aspirin significantly reduced the risk of IS by 20%, albeit at the cost of doubling the risk of major bleeding.19 Consequently, we expect a gradual increase in the adoption of DAPT with aspirin and ticagrelor, although this strategy may increase the likelihood of fatal bleeding events. This study is subject to several limitations. First, due to the de-identification of databases in the CDM, we were unable to obtain detailed clinical information through medical record reviews. Therefore, the accuracy of the recorded rates of underlying diseases might be underestimated, failing to reflect their actual prevalence accurately. Second, we excluded certain antiplatelets, such as ticlopidine, prasugrel, and sarpogrelate, as detailed in the methods section. This exclusion might have led to an overestimation of our findings. Third, the absence of data on stroke subtypes in the CDM databases precluded us from determining whether DAPT with aspirin and clopidogrel was appropriately applied in patients with minor strokes or TIAs following the guidelines of the CHANCE and POINT trials. Nevertheless, we observed a significant increase in DAPT usage among first-ever IS patients subsequent to these landmark trials, highlighting its relevance. Fourth, we did not investigate the time frame between the diagnosis of cerebral infarction and the date of antiplatelet prescription. However, since the inclusion criteria were only for patients with first ever IS and who had never received antiplatelet prescriptions before, it can be assumed that antiplatelet medication was prescribed after cerebral infarction in these patients. Lastly, the possibility that some patients were diagnosed or treated multiple times when transitioning between hospitals cannot be excluded. The ease of transferring between hospitals and the de-identification of records in South Korea complicated the exclusion of such cases. Despite these challenges, this study is the first to utilize CDM data to analyze treatment patterns of antiplatelets among patients with first-ever IS who had no prior use of such medications, offering insights into how landmark trials influence clinical practice. This distributed network analysis of eleven hospital databases indicates that aspirin remains the most frequently prescribed medication for preventing IS. However, following the CHANCE trial, there was a notable and significant increase in the use of DAPT, consisting of aspirin and clopidogrel. As more evidence regarding new P2Y12 inhibitors emerges in the IS domain, examining antiplatelet usage patterns will become crucial for assessing the integration of clinical research and guidelines into everyday practice. Expanding the study to include more institutions and a broader population will enhance our understanding of treatment patterns in the use of antiplatelets. Footnotes Funding: This work was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science and ICT (NRF-2022R1F1A1074643) and Soonchunhyang University. Disclosure: The authors have no potential conflicts of interest to disclose. Author Contributions: Conceptualization: Kim Y.Data curation: Kim Y, Lee KJ.Formal analysis: Kim Y, Lee KJ, Kim J.Funding acquisition: Kim Y.Investigation: Park SH, Kim Y.Methodology: Kim Y, Lee KJ, Kim J.Software: Kim Y, Lee KJ, Kim J.Visualization: Park SH, Kim Y.Writing - original draft: Park SH, Kim Y.Writing - review & editing: Park SH, Lee KJ, Kim J, Seo SI, Lee DY, Park RW, Rhee SY, Cha JM, Yang HJ, Jang JW, Jung S, Lee J, Lee M, Lee SH, Kim C, Bae JS, Kim YJ, Lee JH, Kim Y. Conceptualization: Kim Y. Conceptualization: Kim Y. Data curation: Kim Y, Lee KJ. Data curation: Kim Y, Lee KJ. Formal analysis: Kim Y, Lee KJ, Kim J. Formal analysis: Kim Y, Lee KJ, Kim J. Funding acquisition: Kim Y. Funding acquisition: Kim Y. Investigation: Park SH, Kim Y. Investigation: Park SH, Kim Y. Methodology: Kim Y, Lee KJ, Kim J. Methodology: Kim Y, Lee KJ, Kim J. Software: Kim Y, Lee KJ, Kim J. Software: Kim Y, Lee KJ, Kim J. Visualization: Park SH, Kim Y. Visualization: Park SH, Kim Y. Writing - original draft: Park SH, Kim Y. Writing - original draft: Park SH, Kim Y. Writing - review & editing: Park SH, Lee KJ, Kim J, Seo SI, Lee DY, Park RW, Rhee SY, Cha JM, Yang HJ, Jang JW, Jung S, Lee J, Lee M, Lee SH, Kim C, Bae JS, Kim YJ, Lee JH, Kim Y. Writing - review & editing: Park SH, Lee KJ, Kim J, Seo SI, Lee DY, Park RW, Rhee SY, Cha JM, Yang HJ, Jang JW, Jung S, Lee J, Lee M, Lee SH, Kim C, Bae JS, Kim YJ, Lee JH, Kim Y. References